Corneat Vision, a project invested by GIBF, recently featured on a France TV show with the story the first French patient who received a new and entirely artificial cornea- the Corneat KPro.

The CorNeat KPro is a patented synthetic cornea, keratoprosthesis (KPro), which provides a long-lasting medical solution for corneal blindness, pathology and injury. 

About CorNeat Vision 

CorNeat Vision’s lineup of biomimetic implants blends novel bio-integration technology with innovative ideas to create groundbreaking solutions that address unmet needs in the areas of ophthalmology and periodontology. Our current products biomechanically incorporate with resident tissue providing safe, aesthetic and long-lasting remedies for corneally blind patients and those suffering from glaucoma. These include the CorNeat KPro (artificial cornea), the CorNeat EverPatch (synthetic tissue patch) and the CorNeat eShunt (glaucoma drainage device).

Guangzhou Sino-Israel Biotech Investment Fund (GIBF) has allocated to CorNeat Vision. The money raised is set to be invested in CorNeat’s Chinese subsidiary, which has been set up in Guangzhou – whilst the goal of the investment is ultimately to bolster CorNeats presence and activity in the Chinese market, which includes clinical trials, the setting up of facilities and marketing the company’s first two products